No­vo Nordisk to re­search oral obe­si­ty treat­ment; Dana-Far­ber taps in­to Har­bour Bio­Med's mice plat­form in mul­ti­year deal

No­vo Nordisk and Lu­men Bio­science have en­tered a re­search col­lab­o­ra­tion to ex­plore R&D and man­u­fac­tur­ing with­in obe­si­ty and oth­er meta­bol­ic dis­or­ders, the com­pa­nies an­nounced Wednes­day.

The col­lab­o­ra­tion builds off of re­search sur­round­ing an oral­ly de­liv­ered drug for the GI tract that can be man­u­fac­tured with more scal­a­bil­i­ty and af­ford­abil­i­ty than a typ­i­cal small-mol­e­cule drug. The ini­tial stages of re­search will last about a year, and the 2 com­pa­nies will de­vel­op mol­e­cules us­ing spir­uli­na, a type of cyanobac­te­ria.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER